Kidney International Reports最新文献

{"title":"A Comparison of Hospitalization Outcomes Between Peritoneal Dialysis and Home Hemodialysis Patients by Sex and Race","authors":"George Worthen ,&nbsp;Meghan Day ,&nbsp;Leah Cahill ,&nbsp;Louis-Charles Desbiens ,&nbsp;Annie-Claire Nadeau-Fredette ,&nbsp;Cindy Feng ,&nbsp;Rachel Warren ,&nbsp;Emilie Trinh ,&nbsp;Jeffrey Perl ,&nbsp;Christopher Chan ,&nbsp;David Clark ,&nbsp;Karthik Tennankore","doi":"10.1016/j.ekir.2025.02.012","DOIUrl":"10.1016/j.ekir.2025.02.012","url":null,"abstract":"<div><h3>Introduction</h3><div>As interest in home dialysis as an initial dialysis modality grows, it remains unclear how the different home dialysis modalities may impact hospitalization outcomes, or how this relationship may change depending on patient sex and race.</div></div><div><h3>Methods</h3><div>We compared all-cause hospitalization rates and days in hospital between incident peritoneal dialysis (PD, <em>n</em> = 14,643) and home hemodialysis (HHD patients, <em>n</em> = 875) between January 2005 and December 2018 (last follow-up was in July 2020) using a nationally representative cohort of incident dialysis patients.</div></div><div><h3>Results</h3><div>The overall hospitalization rate was 0.82 hospitalization events per patient-year. Compared with those initiated on PD, HHD patients had a lower hospitalization rate (incident rate ratio [IRR] = 0.78, 95% confidence interval [CI] 0.71–0.85), and spent fewer days in hospital (IRR = 0.68, 95% CI: 0.59–0.78). This was more pronounced in more contemporary cohorts and for males. The protective effect of HHD was stronger for Black patients. When hospitalizations were analyzed by cause, the protective effect of HHD was stronger for infection-related admissions, with Black patients seeing the largest benefit.</div></div><div><h3>Conclusion</h3><div>The type of home modality at dialysis initiation is associated with differences in hospitalization outcomes, an association that is stronger in selected racial groups and sexes. While exploratory in nature, our work highlights the importance of further study on the differential impact of PD and HHD on hospitalization outcomes so that patients incident to dialysis may make an informed decision.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 5","pages":"Pages 1548-1558"},"PeriodicalIF":5.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143922888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New Obesity Guidelines and Implications for CKD","authors":"Tilman B. Drueke ,&nbsp;Andrzej Wiecek ,&nbsp;Ziad A. Massy","doi":"10.1016/j.ekir.2025.03.022","DOIUrl":"10.1016/j.ekir.2025.03.022","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 5","pages":"Pages 1305-1308"},"PeriodicalIF":5.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143923066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"COL4A5-p.Gly624Asp is the Predominant Variant in Europe Associated With a Mild Alport Syndrome Phenotype","authors":"Bastian M. Krüger ,&nbsp;Annika Jens ,&nbsp;Anna Neuhaus ,&nbsp;Jasmina Ćomić ,&nbsp;Riccardo Berutti ,&nbsp;Jonathan de Fallois ,&nbsp;Friederike Petzold ,&nbsp;Johannes Münch ,&nbsp;Jan Kowald ,&nbsp;Tom H. Lindner ,&nbsp;Klemens Budde ,&nbsp;Klara K. Brüning ,&nbsp;Julia Thumfart ,&nbsp;Jacob Haas ,&nbsp;Carolin B. Brigl ,&nbsp;Kerstin Amann ,&nbsp;Velibor Tasic ,&nbsp;Nora Abazi-Emini ,&nbsp;Valbona Nushi-Stavileci ,&nbsp;Jovana Putnik ,&nbsp;Jan Halbritter","doi":"10.1016/j.ekir.2025.02.031","DOIUrl":"10.1016/j.ekir.2025.02.031","url":null,"abstract":"<div><h3>Introduction</h3><div>Pathogenic variants in <em>COL4A3–5</em> are common causes of inherited kidney disease. The clinical presentation extends from classical Alport syndrome (AS) to focal segmental glomerulosclerosis (FSGS) without extrarenal manifestation. In this study, we aimed to assess the genetic and phenotypic spectrum, along with the associated natural histories, in a cohort of patients with AS from 3 tertiary centers in Central Europe.</div></div><div><h3>Methods</h3><div>A total of 210 patients with disease causing variants in one of the <em>COL4A3–5</em> genes were characterized and evaluated for genotype-phenotype correlations. In addition, 48 <em>COL4A5</em>-p.Gly624Asp carriers were analyzed for replication and pooled analysis.</div></div><div><h3>Results</h3><div><em>COL4A5</em>-p.Gly624Asp was by far the most common variant, accounting for 16% of all genetic diagnoses. These patients presented with overall milder renal phenotypes than patients with other <em>COL4A5</em> missense variants and <em>COL4A5</em> glycine-missense variants after age- and sex-matching. In patients lacking a wild-type allele (X-Linked AS [XLAS] males and autosomal recessive AS [ARAS]), histological AS was most frequently observed in kidney biopsies, and truncating variants were associated with increased disease severity. Conversely, in patients with a wild-type allele present (XLAS females and autosomal dominant AS [ADAS]), FSGS was more frequently observed. Predicted protein truncation was not inferior to missense alterations in terms of renal survival.</div></div><div><h3>Conclusion</h3><div>The predominance of the European <em>COL4A5</em> founder variant p.Gly624Asp allowed for the creation of the largest cohort of patients with an identical Alport variant to date, confirming the more favorable renal prognosis specific to this amino acid change. Allelic and gene dosage effects drive phenotypic differences and should be incorporated into future risk models.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 5","pages":"Pages 1372-1383"},"PeriodicalIF":5.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143923076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “PREGNANCY AS A WINDOW TO CURRENT AND FUTURE KIDNEY HEALTH–AN OPPORTUNITY” [Volume 10, Issue 3, March 2025, Pages 645-649]","authors":"Shilpanjali Jesudason ,&nbsp;Liz Lightstone","doi":"10.1016/j.ekir.2025.03.023","DOIUrl":"10.1016/j.ekir.2025.03.023","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 5","pages":"Page 1607"},"PeriodicalIF":5.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143923090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Decoding Glomerular Disease: Baseline Profiles and Insights From the I-TANGIBLE Registry","authors":"Kavita Yadav ,&nbsp;Raja Ramachandran ,&nbsp;Vinod Kumar ,&nbsp;Arun Prabhahar ,&nbsp;Ashok K. Yadav ,&nbsp;Natarajan Gopalakrishnan ,&nbsp;Sourabh Sharma ,&nbsp;Priyamvada P.S. ,&nbsp;Arpita Lahiri ,&nbsp;Manisha Sahay ,&nbsp;Sree Bhushan Raju ,&nbsp;M. Sreelatha ,&nbsp;R. Manorajan ,&nbsp;Pinaki Mukhopadhyay ,&nbsp;Narayan Prasad ,&nbsp;Vamsidhar Veeranki ,&nbsp;Priti Meena ,&nbsp;Harbir S. Kohli ,&nbsp;Sanjay Vikrant ,&nbsp;Vivekanand Jha","doi":"10.1016/j.ekir.2025.02.013","DOIUrl":"10.1016/j.ekir.2025.02.013","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 5","pages":"Pages 1566-1570"},"PeriodicalIF":5.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143923091","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High Temperature Requirement Protein A1–Positive Membranous Nephropathy in a Patient With Chronic Lymphocytic Leukemia","authors":"Ladan Zand ,&nbsp;Fernando C. Fervenza ,&nbsp;Sanjeev Sethi","doi":"10.1016/j.ekir.2025.02.011","DOIUrl":"10.1016/j.ekir.2025.02.011","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 5","pages":"Pages 1600-1601"},"PeriodicalIF":5.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143922882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CKD Progression in Children: Lipid Levels are Another Red Herring","authors":"Stuart L. Goldstein","doi":"10.1016/j.ekir.2025.03.025","DOIUrl":"10.1016/j.ekir.2025.03.025","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 5","pages":"Pages 1324-1325"},"PeriodicalIF":5.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143923132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Experiential Evidence of Systemic Racism for Indigenous Peoples Navigating Transplantation in Canada","authors":"Simone Kennedy ,&nbsp;Robyn Wiebe ,&nbsp;Reetinder Kaur ,&nbsp;Ayumi Sasaki ,&nbsp;Adrienne Charlie ,&nbsp;Alissa Assu ,&nbsp;Allison Jaure ,&nbsp;Jagbir Gill","doi":"10.1016/j.ekir.2025.02.027","DOIUrl":"10.1016/j.ekir.2025.02.027","url":null,"abstract":"<div><h3>Introduction</h3><div>Despite previous data stating that Indigenous patients with kidney failure are 66% less likely to receive a kidney transplant compared with White Canadians, there is a very limited understanding of the barriers and challenges experienced and described by Indigenous Peoples when accessing kidney transplantation. The aim of this study was to describe the perspectives and experiences of Indigenous kidney transplant candidates and recipients, living kidney donors, and Elders on access to kidney transplantation in British Columbia, Canada in the hopes of codeveloping and implementing health services interventions to address systemic barriers to transplantation.</div></div><div><h3>Methods</h3><div>Semistructured interviews were conducted with 19 participants and 4 focus groups were conducted with 18 participants (<em>n</em> = 37). Transcripts were thematically analyzed.</div></div><div><h3>Results</h3><div>Five themes were identified as follows: (i) confronting uncertainty and risk, (ii) culture of giving, (iii) systemic racism and discrimination, (iv) navigating complexities of transplant and donation process, and (v) a lack of culturally safe care.</div></div><div><h3>Conclusion</h3><div>These findings highlight that Indigenous patients face potentially modifiable barriers that may be amenable to health system improvements, such as development of culturally safe patient education tools and Indigenous-specific navigation supports. Health services and policy interventions need to be explored and evaluated to begin to address inequities in access to transplantation.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 5","pages":"Pages 1538-1547"},"PeriodicalIF":5.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143922887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Program Implementation to Achieve Sustainability for Early Detecting of Kidney Diseases and Promoting Kidney Health and Transplantation in Communities","authors":"Ekamol Tantisattamo ,&nbsp;Kamyar Kalantar-Zadeh","doi":"10.1016/j.ekir.2025.03.015","DOIUrl":"10.1016/j.ekir.2025.03.015","url":null,"abstract":"","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 5","pages":"Pages 1594-1595"},"PeriodicalIF":5.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143922892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Persistent B Cell Depletion After Rituximab for Autoimmune and Glomerular Diseases: A Case Series","authors":"Orhan Efe ,&nbsp;Gabriel Sauvage ,&nbsp;Anushya Jeyabalan ,&nbsp;Ayman Al Jurdi ,&nbsp;Harish S. Seethapathy ,&nbsp;Katherine Cosgrove ,&nbsp;Frank B. Cortazar ,&nbsp;Karen A. Laliberte ,&nbsp;Reza Zonozi ,&nbsp;John L. Niles","doi":"10.1016/j.ekir.2025.02.002","DOIUrl":"10.1016/j.ekir.2025.02.002","url":null,"abstract":"<div><h3>Introduction</h3><div>Persistent B cell depletion is a rare complication of rituximab treatment, and its clinical implications are unknown.</div></div><div><h3>Methods</h3><div>This retrospective case series included patients with glomerular and autoimmune diseases who developed persistent B cell depletion (&lt; 5 CD19⁺CD20⁺ cells/μl persisting for &gt; 2 years) after the last rituximab dose.</div></div><div><h3>Results</h3><div>Among 1519 patients who received rituximab, 2% (<em>n</em> = 30) had persistent B cell depletion. The frequencies of persistent B cell depletion were 2.5% (22 of 878), 2.4% (2 of 82), and 0.8% (1 of 114) in antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV), systemic lupus erythematosus (SLE) or lupus nephritis, and podocytopathies, respectively. The remaining patients had ANCA-negative vasculitis (<em>n</em> = 2), anti-glomerular basement membrane disease (<em>n</em> = 1), Behcet’s disease (<em>n</em> = 1), and polymyositis (<em>n</em> = 1). The median age was 64.5 (interquartile range [IQR]: 44–77) years. Before the last dose of rituximab, all patients except 2 used cytotoxic agents, often prolonged (&gt; 1 year) or recycling courses, and 60% (18 of 30) received a period of long-term maintenance steroids. By 4 years after the last rituximab dose, only 30% had B cell repopulation. In those who experienced B cell repopulation, B cell counts remained very low, at a median of 7(6–15) cells/μl at the last follow-up. After the last rituximab dose, 83% (23 of 30) had sustained disease remission. Late-onset neutropenia, recurrent infections, and severe infections occurred in 23% (7 of 30), 47% (14 of 30), and 57% (17 of 57), respectively. Of the patients, 23% (7 of 30) required immunoglobulin replacement, and 30% (9 of 30) died, mostly from complications of chronic diseases.</div></div><div><h3>Conclusion</h3><div>Persistent B cell depletion is a rare complication of rituximab treatment, mostly affecting patients with exposure(s) to cytotoxic therapies for recurrent diseases. It is characterized by prolonged disease remission and increased infection risk.</div></div>","PeriodicalId":17761,"journal":{"name":"Kidney International Reports","volume":"10 5","pages":"Pages 1441-1449"},"PeriodicalIF":5.7,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143922972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}